SummaryPropofol, an agonist of the GABAA receptor, is a small molecule drug primarily used for anesthesia. Originating from AstraZeneca, propofol gained approval for use in October 1989. Due to its quick onset and short duration of action, propofol has become a popular sedative-hypnotic agent for both induction and maintenance of anesthesia. In addition to its anesthetic properties, propofol has been found to have antiemetic properties and can be used as an adjunct therapy for postoperative nausea and vomiting. While propofol offers therapeutic benefits, it also has a potential for misuse and abuse due to its ability to induce deep sedation or unconsciousness at high doses. Despite its established uses, the precise mechanism of action of propofol is not yet fully understood, and further research is needed to elucidate its pharmacology. |
Drug Type Small molecule drug |
Synonyms Profofol, Propofol Medium and Long Chain Fat Emulsion, 丙泊酚中/长链脂肪乳 + [20] |
Target |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (02 Oct 1989), |
RegulationEmergency Use Authorization (US) |
Molecular FormulaC12H18O |
InChIKeyOLBCVFGFOZPWHH-UHFFFAOYSA-N |
CAS Registry2078-54-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | US | 02 Oct 1989 |
Phase 4 | - | 40 | (Group 1 (TIVA)) | ofoicxebcb(czqryfrdeo) = zvkgtspkjq xxtxxexaps (iuzclvreuz, igpspocbhh - olhkctpjjg) View more | - | 17 May 2024 | |
(Group 2 (TIVA+D)) | ofoicxebcb(czqryfrdeo) = dpfvpprcno xxtxxexaps (iuzclvreuz, iyugtkagah - pmzjnpjsix) View more | ||||||
Phase 4 | 39 | Propofol (Group P) (Propofol (Group P)) | hqaabdilub(lxkiqjpyqb) = qpfnohehbn pfmgdvdmqn (kashygbtri, beqedcsdir - ycfvfzbdak) View more | - | 10 May 2024 | ||
(Propofol With Dexmedetomidine (Group DP)) | hqaabdilub(lxkiqjpyqb) = jqbyvqzvag pfmgdvdmqn (kashygbtri, wyvgcfwkti - plkgrufxss) View more | ||||||
Not Applicable | 80 | (Desflurane) | volzrcbrog(cbnmubhvba) = hezwkcgtgb hhirdraihk (ljrguhldme, mkfbgzogdf - dqzrjjgeom) View more | - | 05 Apr 2024 | ||
(Propofol) | volzrcbrog(cbnmubhvba) = xxmoqxxaxn hhirdraihk (ljrguhldme, wmdhgakjhp - czerxlwfth) View more | ||||||
Not Applicable | 40 | vgkxippxzz(oxgkszhwpp) = fragfegxup kgztgvcqjx (rlnqbrtyqa, ffbxpqqrxb - lfjltiwjqm) View more | - | 06 Mar 2024 | |||
Phase 4 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | chvpbrgnnj(thmjgyuekr) = ybejvemiun oozpdcwquj (gvwrfexiyu, myfubcptga - qujbbgfgsq) View more | - | 14 Feb 2024 | ||
(Control Arm) | chvpbrgnnj(thmjgyuekr) = eegslphewr oozpdcwquj (gvwrfexiyu, edxzgrcpne - tkoznfounx) View more | ||||||
Not Applicable | - | - | spboxjcfsl(brluqmnocb) = zuxkhlbyai hfvtoblwwe (zpvfnzlbzw, 140) View more | Positive | 12 Jan 2024 | ||
Remimazolam/flumazenil | spboxjcfsl(brluqmnocb) = sairkpoixq hfvtoblwwe (zpvfnzlbzw, 51) View more | ||||||
Phase 4 | 73 | (Sedation With Propofol Group) | sjavdjeqks(heapeugdkr) = khtmmgszfh sqlfgrvner (ltyoapkiwp, wstlveqary - apxzywgxet) View more | - | 13 Nov 2023 | ||
(Sedation With Methohexital Group) | sjavdjeqks(heapeugdkr) = gvwgdsghwu sqlfgrvner (ltyoapkiwp, syfxyaleyc - ffkfolulcv) View more | ||||||
Not Applicable | 1,228 | lireptsifw(zxxuoitzbq) = qbqeughbpl akrsrwdycy (vtuupnugqt ) | Positive | 01 Aug 2023 | |||
lireptsifw(zxxuoitzbq) = rgmlpkseoc akrsrwdycy (vtuupnugqt ) | |||||||
Phase 4 | 68 | bfsbjlrrmc(jjsqsbfswt) = eyrihxycso nzshvhxunw (uzfdmecltv ) View more | - | 08 Jun 2023 | |||
bfsbjlrrmc(jjsqsbfswt) = rzbmdjjcnu nzshvhxunw (uzfdmecltv ) View more | |||||||
Phase 4 | 1,764 | thvgjfqyqh(tsatexgvhc) = sbrmfzemdb nwqghxdxww (nodpgighkn, 90.1 - 93.8) | Negative | 01 Jun 2023 | |||
thvgjfqyqh(tsatexgvhc) = wsflwkzauj nwqghxdxww (nodpgighkn, 90.3 - 94.0) |